Organism | Antimicrobial | MIC (mg/L) | %S + %Ia | %R | |
---|---|---|---|---|---|
MIC90 | Range | ||||
P. aeruginosa, MDR (n = 1281) | Piperacillin-tazobactam | ≥256 | ≤0.25–≥256 | 8.7 | 91.3 |
Aztreonam | 128 | 0.12–≥256 | 36.5 | 63.5 | |
Ceftazidime | ≥256 | 0.06–≥256 | 19.1 | 80.9 | |
Ceftazidime-avibactam | 64 | ≤0.015–≥256 | 62.9 | 37.1 | |
Cefepime | 32 | 0.5–≥64 | 19.1 | 80.9 | |
Imipenem | ≥16 | ≤0.03–≥16 | 17.1 | 82.9 | |
Meropenem | ≥32 | ≤0.06–≥32 | 38.6 | 61.4 | |
Levofloxacin | ≥16 | ≤0.03–≥16 | 9.6 | 90.4 | |
Colistin | 1 | ≤0.06–≥16 | 99.5 | 0.5 | |
Amikacin | 64 | ≤0.25–≥128 | 61.3 | 38.7 | |
P. aeruginosa, carbapenemase positive/ MBL-negative (n = 53) | Piperacillin-tazobactam | ≥256 | 16–≥256 | 3.8 | 96.2 |
Aztreonam | ≥256 | 2–≥256 | 28.3 | 71.7 | |
Ceftazidime | ≥256 | 4–≥256 | 5.7 | 94.3 | |
Ceftazidime-avibactam | 32 | 1–≥256 | 71.7 | 28.3 | |
Cefepime | ≥64 | 4–≥64 | 15.1 | 84.9 | |
Imipenem | ≥16 | 8–≥16 | 0.0 | 100 | |
Meropenem | ≥32 | 8–≥32 | 3.8 | 96.2 | |
Levofloxacin | ≥16 | 0.5–≥16 | 5.7 | 94.3 | |
Colistin | 1 | 0.25–4 | 98.1 | 1.9 | |
Amikacin | 64 | 2–≥128 | 30.2 | 69.8 | |
P. aeruginosa, MBL-positive (n = 251)b | Piperacillin-tazobactam | ≥256 | 4–≥256 | 5.6 | 94.4 |
Aztreonam | 64 | 0.25–≥256 | 56.6 | 43.4 | |
Ceftazidime | ≥256 | 8–≥256 | 1.6 | 98.4 | |
Ceftazidime-avibactam | ≥256 | 2–≥256 | 2.8 | 97.2 | |
Cefepime | ≥64 | 8–≥64 | 4.4 | 95.6 | |
Imipenem | ≥16 | 4–≥16 | 0.8 | 99.2 | |
Meropenem | ≥32 | 4–≥32 | 3.2 | 96.8 | |
Levofloxacin | ≥16 | 0.5–≥16 | 1.6 | 98.4 | |
Colistin | 1 | 0.25–2 | 100 | 0.0 | |
Amikacin | ≥128 | 2–≥128 | 19.1 | 80.9 |